(Q50538417)

15 March 2018

title

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. (English)

1 reference

15 March 2018

1 reference

1 reference

Christopher S Ambrose

2

1 reference

15 March 2018

Roger Baxter

8

object named as

Roger Baxter

1 reference

15 March 2018

author name string

Seth L Toback

1

1 reference

15 March 2018

Abigail Eaton

3

1 reference

15 March 2018

John Hansen

4

1 reference

15 March 2018

Laurie Aukes

5

1 reference

15 March 2018

Ned Lewis

6

1 reference

15 March 2018

Xionghua Wu

7

1 reference

15 March 2018

language of work or name

English

0 references

publication date

6 February 2013

1 reference

15 March 2018

published in

Vaccine

1 reference

15 March 2018

volume

31

1 reference

15 March 2018

issue

14

1 reference

15 March 2018

page(s)

1812-1818

1 reference

15 March 2018

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Comparison of epidemiologic methods for active surveillance of vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

7 January 2021

Urticaria and infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

Adverse events reported following live, cold-adapted, intranasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.055

10.1016/J.VACCINE.2013.01.055

7 January 2021

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018